ReCode Therapeutics is a genetic medicines company that specializes in mRNA and gene correction therapeutics.
ReCode Therapeutics has raised $29.4M in total funding. The most recent round was Debt Financing. The last funding was announced in September 2025.
ReCode Therapeutics's investors include Sanofi Ventures, Vida Ventures, OrbiMed, Pfizer Venture Investments, OUP (Osage University Partners).
ReCode Therapeutics is headquartered in Dallas, United States.
ReCode Therapeutics is a genetic medicines company that specializes in mRNA and gene correction therapeutics.
ReCode Therapeutics is at the Debt Financing stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ReCode Therapeutics — Funding & Investors." VCBacked, September 29, 2025, https://www.vcbacked.co/company/recode-therapeutics. Accessed October 29, 2026.
VCBacked. (2025). ReCode Therapeutics — Funding & Investors. Retrieved October 29, 2026, from https://www.vcbacked.co/company/recode-therapeutics
{{cite web |title=ReCode Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/recode-therapeutics |website=VCBacked |access-date=October 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated